Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

47.65 +0.50 (+1.06%)
Streaming Delayed Price Updated: 3:23 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Looking Into Sanofi's Recent Short Interest
Via Benzinga
(SNY) - Analyzing Sanofi's Short Interest
Via Benzinga
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
Travere Therapeutics Inc (NASDAQ: TVTX) announced 
Via Benzinga
Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis, Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs, Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories
Benzinga 
Via Benzinga
FDA Rejects EpiPen Alternative - ARS Pharmaceuticals' Allergic Reaction Nasal Spray
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type... 
Via Benzinga
Exposures Product Safety
2 Top Biotech Stocks to Buy Right Now
These drugmakers are among the most dominant in the world. 
Via The Motley Fool
Why Shares of MacroGenics Are Jumping Thursday
The company announced second-quarter earnings. 
Via The Motley Fool
3 Stocks to Buy to Ride Europe’s Coming Market Surge
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave. 
Via InvestorPlace
Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs
On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics,  
Via Benzinga
Exposures COVID-19
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now
This market is currently in its infancy. 
Via The Motley Fool
'Transformative Event' For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi
First Wave BioPharma Inc (NASDAQ: FWBI) announced an agreement with Sanofi SA (NASDAQ: SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop... 
Via Benzinga
Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm
Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony. 
Via InvestorPlace
Looking Into Sanofi's Recent Short Interest
Via Benzinga
The Top Healthcare Stocks to Buy With $100
There's no need to have a fortune to invest in stocks. 
Via The Motley Fool
Sanofi (SNY) Q2 2023 Earnings Call Transcript
SNY earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite. 
Via Investor's Business Daily
Could This Medicine Be the Next Winner for Novartis?
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials. 
Via The Motley Fool
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth... 
Via Benzinga
Exposures Product Safety
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
Neither is performing particularly well this year compared to the broader market, but don't let that chase you away. 
Via The Motley Fool
Amazon's Boon for Diabetes Patients - Streamlining Pharmacy Discounts
Amazon.Com Inc's (NASDAQ: AMZN) online pharmacy launched a new initiativ 
Via Benzinga
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Tiziana Life Sciences, Inc. 
Via Benzinga
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary... 
Via Benzinga
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
iPhone US Shipments Take A Hit, Does Social Media Algorithm Impact Political Beliefs? Research Reveals Answer, Disney Joins Netflix To Crack Down Password Sharing In India: Today's Top Stories
Bloomberg 
Via Benzinga
Sanofi Reports Lower Q2 Earnings, But Lifts 2023 Outlook On New Drug Launches
Sanofi SA (NASDAQ: SNY) reported a 1% decline in Q2 business operating in 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.